Answer:
a. $203.125
Explanation:
Calculation to determine the net profit/loss on this option to the investor
Net profit/loss=((1.900 - 1.885) - 0.0215)(31,250)
Net profit/loss=(0.015-0.0215)*31,250
Net profit/loss=0.0065*31,250
Net profit/loss=$203.125
Therefore the net profit/loss on this option to the investor will be $203.125
Answer:
The statement is: True.
Explanation:
A competitive advantage is an advantage an individual, organization or country has over its competitors. That competitive advantage can be a comparative advantage when the entity has found a way to implement lower opportunity costs in its production process or a differential advantage if the firm provides a product or service with a unique feature difficult to replicate by competitors.
Answer:
$12.22 per share
Explanation:
The computation of the stock price one year from now is shown below;
Current EPS = Net Income ÷ Number of shares
= $95,000,000/5,500,000
= $17.2727
Now
P/E Ratio = Market Price per share ÷ Earnings per share
= $14.75 ÷ 17.2727
= 0.8539 times
Now
Revised EPS = $95,000,000 × 1.25 ÷ 8,300,000
= $14.3072
So, the Price is
= 14.3072 × 0.8539
= $12.22 per share
Answer:
indicates what percent decline in sales could be sustained before the company would operate at a loss.
Explanation:
Since, Margin of safety ratio = Expected Sales - Break even sales
therefore,
The correct statement is : The margin of safety ratio indicates what percent decline in sales could be sustained before the company would operate at a loss.
Answer: credible commitment
Explanation:
From the question, we are informed that BioGrow Pharma Inc. wanted its research partner, an R&D company, to develop a cancer vaccine but that the project required huge capital investments, and its research partner was not ready to solely face the risks involved.
Therefore, to gain its partner's confidence and to prove its involvement, BioGrow Pharma invested $100 million in the project. This investment made by BioGrow Pharma will result in a credible commitment.
